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Abstract 
Objective: We conducted a retrospective cohort study to assess the effect of tracking People Living with HIV (PLHIV) 
after missed clinic visits and factors associated with return to care in rural Uganda. We assessed retention in care 
among 650 HIV‑infected women and men. We used univariable and multivariable generalized linear models to assess 
demographic and self‑reported factors associated with re‑engagement in HIV care.
Results: Of 381 PLHIV who ever missed a scheduled appointment, 68% were female and most (80%) had initi‑
ated ART. Most (70%) of those tracked returned to care. Relative to men, women (adjusted risk ratio [ARR] 1.23; 95% 
confidence interval (CI) 1.05–1.43; p = 0.009) were more likely to return to care after active tracking. PLHIV who missed 
scheduled visits for other reasons (forgetting, adequate drug supplies, or long distance to clinic) had reduced odds of 
return to care (ARR 0.41; 95% CI 0.28–0.59; p < 0.001). These data support close monitoring of patient retention in HIV 
care and active measures to re‑engage those who miss an appointment. Furthermore, they highlight the need for 
targeted interventions to those more resistant to re‑engagement such as men.
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Introduction
Uganda is one of 15 countries that accounted for 75% of 
the 2.1 million new HIV infections that occurred in 2015 
[1]. Uganda has scaled up coverage of antiretroviral ther-
apy (ART), which durably suppresses plasma and geni-
tal tract viral load, decreases HIV-associated mortality, 
and prevents HIV transmission [2, 3]. The proportion of 
HIV-infected adults receiving ART in Uganda increased 
from an estimated 37–57% in 2011 to 81% in 2016/2017 
[4]. Increased ART coverage was accompanied by a 51% 
decrease in the number of new HIV infections and a 45% 
reduction in HIV-related mortality between 2010 and 
2016 [5].
Patient retention in HIV care is key to achieving Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 
and national 90-90-90 targets: 90% of all people with 
HIV to be diagnosed and know their status, 90% of all 
HIV-infected people to receive ART, and 90% of per-
sons receiving ART to be virally suppressed by 2020 [6, 
7]. Continuous engagement with the healthcare system 
by HIV infected individuals is a key challenge for HIV 
treatment programs [8]; losses occur at each step of the 
HIV care cascade [9], and most attrition occurs during 
the first 24 months of ART [10]. Despite the personal and 
public health benefits of HIV treatment, global retention 
in care on ART at 12 months was approximately 74% in 
2016 [11]. In Uganda, attrition rates of up to 20% have 
been reported 12 months after ART initiation [12].
Persons not retained in care experience treatment 
interruptions and viral non-suppression, which increases 
risk of drug resistant virus, and compromises personal 
and population-level benefits of ART [11]. Although 
no uniform definition of retention in care exists, at 
least one visit to an HIV care provider every 6  months 
is typically used to allow for clinically stable and viro-
logically suppressed PLHIV who require fewer provider 
interactions [13–17]. Strategies to improve retention 
in HIV care include peer support, targeted counselling, 
mobile phone tracking and home visits [13]. Targeted 
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retention interventions could minimize ART interrup-
tions and reduce HIV-related morbidity and mortality 
[11]. We undertook a study at a rural government hos-
pital in North-Eastern Uganda, with specific challenges 
of an agro-pastoralist community which practices semi-
nomadic livestock rearing and whose settlement pat-
terns are determined by availability of pasture and water 
sources [18]. We assessed the effect of patient tracking 
using phone calls and/or home visits on return to care 




Between January 2014 and August 2015, we conducted a 
retrospective cohort study of PLHIV receiving HIV care 
at Moroto Regional Referral Hospital (RRH). The HIV 
program at this facility was supported by the Civil Soci-
ety Fund Regional Referral Hospitals Project [19]. We 
included in the study PLHIV who enrolled in the ART 
clinic during the study period, missed a scheduled visit, 
and had medical records in the Open Medical Records 
System  (OpenMRS®) database. Those who missed a 
scheduled clinic visit were contacted by telephone after 
5 days (Fig. 1). The clinic had a designated counsellor to 
actively track persons who missed one or more visits. If 
the PLHIV had no telephone contact or failed to return to 
the clinic after several calls, a home visit was conducted by 
clinic staff, an expert client or a peer leader. PLHIV were 
tracked for 3  consecutive months after a missed sched-
uled visit. Those who did not return were flagged as lost to 
follow-up. These active tracking measures were intended 
to encourage PLHIV to return to active follow-up, address 
psychosocial issues and better understand circumstances 
that led to failure to turn up for the scheduled clinic visit. 
Data on PLHIV age, gender, ART status, tracking method, 
return to clinic, and reason(s) for missed visits were col-
lected on PLHIV tracking/follow-up forms.
Statistical analysis
Return to care (the primary outcome) was defined as return 
to care within 3 months of being tracked. Descriptive sta-
tistics and frequency distributions were performed for 
continuous and categorical data, respectively. To identify 
factors associated with returning to care after active track-
ing, we categorized PLHIV who were tracked after missing 
an appointment by whether they did or did not return to 
care. A generalized linear model was used to estimate risk 
ratios of return to care after adjusting for underlying differ-
ences in predictor variables (age, gender, ART status, mode 
of contact and reason(s) for missing scheduled clinic visit). 
Significance was set at p < 0.05. Data were analyzed using 
Stata version 14 (StataCorp LLC, College Station, Texas).
Results
Of the 650 persons in HIV care during the study period, 
381 (59%) had ever missed a scheduled clinic visit and 
were included in the present analysis. For these 381, 
the median age was 30 years [interquartile range (IQR), 
23–35], 259 (68%) were female and 306 (80%) had initi-
ated ART (Table  1). Overall, 598 phone calls and 472 
home visits were conducted during the study period.
Seventy percent of PLHIV tracked by phone call and/or 
home visits returned to care. Of these, 74% were women. 
PLHIV were as likely to return to care after being tracked 
through a phone call as through home visit (73% vs. 64%; 
p = 0.08). Of the 42% who self-reported missing sched-
uled clinic visits because of having travelled away from 
home, most (67%) were women. Forty-three percent 
reported socio-structural barriers to retention in care 
including forgetting the scheduled appointment, long 
distance to clinic, tight work schedules, stigma, ART side 
effects, having adequate supplies of drugs, and lack of 
food. The remaining 15% were unreachable or not avail-
able when tracked by phone and/or home visit.
In multivariable analyses, women were more likely to 
return to care after active tracking than men (adjusted 
risk ratio [ARR] 1.23; 95% CI 1.05–1.43; p = 0.009). Com-
pared with persons who had travelled, those who were 
unavailable/unreachable at time of contact (ARR 0.85; 
95% CI 0.75–0.95; p = 0.01) and those that reported other 
reasons for missing their scheduled appointments e.g., 
long distance to clinic, stigma, still having drug supplies 
Fig. 1 PLHIV contact (phone call and/or home visit) flow diagram. 
PC, phone call; HV, home visit; C, contacted; NC, not contacted; R, 
returned; NR, not returned; LTFU, lost to follow up
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or forgetting the appointment (ARR 0.41; 95% CI 0.28–
0.59; p < 0.001) were less likely to return to care after 
missing a scheduled visit. Age, ART status and tracking 
method were not related to return to care (p = 0.27, 0.12 
and 0.83, respectively).
Discussion
In this retrospective cohort study of HIV-infected Ugan-
dan adults, in which PLHIV who missed scheduled vis-
its were actively followed through phone contact and/or 
home visits, most returned to care after being tracked. 
Female gender and prior receipt of ART were predic-
tors of return to HIV care. Those who reported non-
travel reasons for missed visits, or were unreachable by 
designated personnel, were significantly less likely to be 
retained in HIV care.
We found that women and PLHIV on ART were more 
likely to return to HIV care after missing a scheduled 
clinic visit. This finding is in agreement with prior stud-
ies in which gender and ART status were associated with 
return to care after tracking [16, 20–22]. In a systematic 
review of 42 studies from 12 countries, factors associ-
ated with lower retention rates included younger age, 
male gender, stigma, non-disclosure of HIV status, fear of 
drug side effects, and transport costs [23]. Other studies 
have found that denial of HIV status, healthy status per-
ception, substance use, mental illness, distrust of medi-
cal providers, and side effects of HIV medications were 
associated with poorer retention [14, 23, 24]. Address-
ing these factors could increase the likelihood of staying 
engaged and retained in HIV care. In our study, a sig-
nificantly higher proportion of men did not re-engage in 
care after active tracking. In East and Southern Africa, 
ART coverage is lower among men than women (57% vs 
72%) [25], and men are less likely than women to adhere 
to HIV treatment resulting in poorer outcomes [26, 
27]. Cultural constructs of masculinity and HIV stigma 
appear to influence health seeking behavior and com-
promise HIV care utilization in this setting [27]. HIV 
providers should utilize culturally appropriate initiatives 
to encourage health-enabling masculinities and support 
retention in care.
The proportion of PLHIV who ever missed a scheduled 
clinic visit in our study is similar to that reported in other 
studies of mobile populations [15, 16, 22]. Some PLHIV 
may have cycled in and out of care, given the mobile 
nature of the study population [9]. We observed that 
most PLHIV who were traced re-engaged in HIV care. 
Active tracing and linkage to care likely account for these 
findings. Monitoring retention on ART is key to estimat-
ing the proportion disengaging from care and developing 
targeted interventions to improve engagement in care, 
decreasing mortality, and minimizing adverse treatment 
outcomes [11]. Ancillary services such as case manage-
ment, outreach, support groups, and patient navigation 
could further improve retention in care and facilitate 
attainment of national and global HIV treatment goals 
[28–33].
In our study, clinical, structural and psychosocial bar-
riers to retention in care included long distance travel 
to clinic, tight work schedules, stigma, ART side effects, 
forgetting the scheduled appointment and food inse-
curity. This study was undertaken in Karamoja region. 
The region has poorer health outcomes than elsewhere 
Table 1 Distribution of  patient characteristics stratified by  return to  HIV care and  predictors of  return to  care having 
missed a scheduled appointment after tracking
Characteristic N (%) or median (IQR) Did not return to HIV 
care (n = 114)
Returned to HIV 
care (n = 267)
p-value Adjusted OR (95% CI) p-value
Age in years, median (IQR) 30 (25–36) 29 (22–34) 0.01 0.99 (0.98–1.01) 0.265
Gender
 Male 53 (43.4) 69 (56.6) < 0.001 Reference
 Female 61 (23.5) 198 (76.5) 1.23 (1.05–1.43) 0.009
ART status
 ART naive 33 (44.0) 42 (56.0) 0.003 Reference
 On ART 81 (26.5) 225 (73.5) 1.16 (0.96–1.39) 0.119
Tracking method
 Phone call 63 (26.7) 173 (73.3) 0.08 Reference
 Home visit 51 (35.2) 94 (64.8) 0.98 (0.87–1.11) 0.832
Reason for missing appointment
 Travelled 51 (31.5) 111 (68.5) < 0.001 Reference
 Unavailable 38 (67.9) 18 (32.1) 0.85 (0.75–0.95) 0.006
 Other 25 (15.3) 138 (84.7) 0.41 (0.28–0.59) < 0.001
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in Uganda due to a combination of environmental, geo-
graphical, economic and cultural issues leading to con-
flict, food insecurity and malnutrition, high alcohol rates, 
gender based violence and low education rates [34]. 
Despite these difficulties, our findings are in striking 
agreement with other work from sub-Saharan Africa in 
which 65% reported structural barriers (transportation, 
distance to clinic, poverty), 33% reported clinic-based 
barriers (long waiting times), and 27% reported psycho-
social barriers (social support, stigma and non-disclosure 
of HIV status) to retention in care [35]. These socio-
structural factors are major determinants of retention in 
HIV care [36]. Accessing HIV care closer to home may 
decrease the cost and disruption of ART non-adherence. 
Community-based ART delivery programs, in which 
ART is delivered to consenting, stable participants at 
community drug distribution points, improve access to 
HIV treatment services, ART adherence and retention 
in care in resource-limited settings [37]. This alternative 
delivery model provides drug refills every 2–3  months, 
decreases waiting times, reduces travel time and costs, 
and provides psychosocial support by expert clients, 
thereby reducing the impact of socio-structural barri-
ers on retention in care [37]. Community drug distribu-
tion points are an effective alternative delivery model 
which should be scaled up to improve retention in care in 
resource-limited settings.
Conclusion
In conclusion, we found that nearly half of HIV-infected 
adults attending a rural HIV clinic in a region with 
poor health outcomes had ever missed a scheduled 
visit. Seven-in-ten PLHIV returned to HIV care follow-
ing active tracing using home visits and phone calls. 
These data support active monitoring of patient reten-
tion in ART care and highlight the need for targeted 
interventions to engage men and others who struggle to 
maintain engagement in care especially in challenging 
environments.
Limitations
Our study has limitations. We did not collect mortal-
ity data and those who returned to care may have been 
more likely to be healthy. Data were collected from a 
public sector clinic and there were considerable miss-
ing data. We did not evaluate socio-economic variables 
including level of education, occupation, marital status 
and disclosure of HIV status because these data are not 
routinely collected. Finally, we did not document CD4 
counts, HIV viral load, and ART regimen to objectively 
assess HIV treatment outcomes after return to care. 
These factors may limit the generalizability of our find-
ings. Nevertheless, we demonstrated that a substantial 
proportion of PLHIV re-engaged in HIV care following 
active tracing in a rural, resource-limited ART clinic.
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